3 Specialty Chemicals Maker, Pharmaceutical Ingredients Maker and Commercial Vehicles Maker Stocks With a Strong Future Roadmap: Clean Science and Technology, Divi's Laboratories and Ashok Leyland

Specialty chemical, drug input and truck stocks give investors a way to track businesses that sit close to everyday demand in India. Clean Science and Technology, Divi's Laboratories and Ashok Leyland cover a specialty chemicals maker, a pharmaceutical ingredients maker and a commercial vehicles maker.

This list covers three specialty chemical, drug input and truck stocks with complete current figures: Clean Science and Technology, Divi's Laboratories and Ashok Leyland. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Specialty Chemical, Drug Input and Truck Stocks?

Specialty chemical, drug input and truck stocks are listed companies that make performance and specialty chemicals for consumer and industrial products, produce active pharmaceutical ingredients and intermediates for global drug makers, and build trucks, buses and defence vehicles. Their earnings depend on chemical demand, pharma sourcing and freight and passenger transport.

Specialty Chemical, Drug Input and Truck Stocks at a Glance

On valuation, Clean Science and Technology and Ashok Leyland trade at a P/E below the industry P/E, while Divi's Laboratories trades above it, which reflects the growth the market already expects. Readers comparing specialty chemical, drug input and truck stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in specialty chemical, drug input and truck stocks can use the coming numbers to test whether growth is holding.

Why Do Specialty Chemical, Drug Input and Truck Stocks Have a Strong Roadmap in India?

Specialty chemical, drug input and truck stocks have a strong roadmap in India because global supply chain shifts toward India, steady demand for generic medicines and growing freight and passenger movement keep widening the market for these companies.

• Specialty chemicals. Global buyers add Indian chemical suppliers.
• Pharma ingredients. Drug makers need dependable inputs.
• Commercial vehicles. Freight and bus fleets keep expanding.

Why Clean Science and Technology Features Among These Specialty Chemical, Drug Input and Truck Stocks

Among the specialty chemical, drug input and truck stocks on this list, Clean Science and Technology makes specialty chemicals including performance chemicals, pharma intermediates and FMCG chemicals using its own catalytic processes.

Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%.

In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1.

Roadmap: The company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.

What to watch: Watch new product launches and capacity utilisation at its newer plants.

Why Divi's Laboratories Features Among These Specialty Chemical, Drug Input and Truck Stocks

Among the performance chemical, drug input and commercial vehicle shares on this list, Divi's Laboratories is a Hyderabad-based maker of active pharmaceutical ingredients, intermediates and custom synthesis products, serving large global pharma companies from large-scale manufacturing sites.

In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%.

Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0.

Roadmap: The company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

What to watch: Check the order flow in custom synthesis and the commissioning of new capacity.

Why Ashok Leyland Features Among These Specialty Chemical, Drug Input and Truck Stocks

Among the three companies on this list, Ashok Leyland is a Chennai-based commercial vehicle maker, producing trucks, buses, light commercial vehicles, defence vehicles and engines for domestic and export customers.

The company has a return on equity of 24.4%, a debt to equity ratio of 4.49 and a market capitalisation of Rs 85,729 crore. The stock trades at a P/E of 23.0, below the industry P/E of 23.4.

Revenue rose from Rs 26,324 crore in FY22 to Rs 56,947 crore in FY26, a compound annual growth rate of 21.3%. Net profit grew from Rs 1,359 crore in FY23 to Rs 3,721 crore in FY26, which works out to a compound annual growth rate of 39.9%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 13,258 crore, while net profit rose 1.5% to Rs 668 crore.

Roadmap: The company is growing in light commercial vehicles and electric buses and is widening its presence in export markets. Rising freight activity and fleet replacement support steady demand for its trucks and buses.

What to watch: Track commercial vehicle demand, order wins for buses and export progress.

Clean Science and Technology vs Divi's Laboratories vs Ashok Leyland on Key Financials

The table below sets the three specialty chemical, drug input and truck stocks side by side on revenue, profit and margin, using reported figures.

Ashok Leyland posts the highest return on equity in this group at 24.4%. Ashok Leyland combines the largest FY26 revenue at Rs 56,947 crore with the fastest revenue growth, a 21.3% compound annual rate. A useful habit with specialty chemical, drug input and truck stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several chemical intermediate, API and bus and truck stocks instead of one name, which keeps a single result from deciding the outcome.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Specialty Chemical, Drug Input and Truck Stocks

Every theme carries risks that deserve a check before any decision. For these specialty chemical, drug input and truck stocks, the main points are: Long-term performance chemical, drug input and commercial vehicle shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Raw material and energy costs. Input prices can move margins in chemicals.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Production cycles. Vehicle output can vary with demand.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter specialty chemical, drug input and truck stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Specialty Chemical, Drug Input and Truck Stocks

Specialty chemical, drug input and truck stocks work best when investors track growth, valuation and return on equity side by side. Clean Science and Technology, Divi's Laboratories and Ashok Leyland each have a clear plan to grow. Based on the 10 November 2026 close, Clean Science and Technology trades at Rs 695.95, Divi's Laboratories at Rs 11,565.5 and Ashok Leyland at Rs 174.86. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these specialty chemical, drug input and truck stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track specialty chemical, drug input and truck stocks, set price alerts and get research-backed stock ideas.

What are specialty chemical, drug input and truck stocks?

Ans. Specialty chemical, drug input and truck stocks are listed companies that make performance and specialty chemicals for consumer and industrial products, produce active pharmaceutical ingredients and intermediates for global drug makers, and build trucks, buses and defence vehicles. Their earnings depend on chemical demand, pharma sourcing and freight and passenger transport. This list looks at three of them, Clean Science and Technology, Divi's Laboratories and Ashok Leyland, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.

Which specialty chemical, drug input and truck stocks are covered in this list?

Ans. This list covers Clean Science and Technology, Divi's Laboratories and Ashok Leyland. Based on the 10 November 2026 close, Clean Science and Technology traded at Rs 695.95, Divi's Laboratories at Rs 11,565.5 and Ashok Leyland at Rs 174.86. Their return on equity ranges from 14.5% to 24.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 5.1% to 21.3%.

Why do specialty chemical, drug input and truck stocks have a strong future roadmap in India?

Ans. Specialty chemical, drug input and truck stocks have a strong roadmap in India because global supply chain shifts toward India, steady demand for generic medicines and growing freight and passenger movement keep widening the market for these companies. The main drivers are as follows. Specialty chemicals. Global buyers add Indian chemical suppliers. Pharma ingredients. Drug makers need dependable inputs. Commercial vehicles. Freight and bus fleets keep expanding. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Clean Science and Technology performed financially?

Ans. Revenue rose from Rs 715 crore in FY22 to Rs 989 crore in FY26, a compound annual growth rate of 8.5%. Net profit for FY26 was Rs 230 crore, a net margin of 23.2%. In the June 2026 quarter, revenue grew 13.4% year on year to Rs 291 crore, while net profit rose 4.7% to Rs 73.3 crore. The company has a return on equity of 14.5%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 8,080 crore. The stock trades at a P/E of 34.7, below the industry P/E of 35.1. Looking ahead, the company uses cleaner, in-house developed processes that give it cost advantages in products such as MEHQ and guaiacol. It is adding new products and capacity, and carries no debt.

How has Divi's Laboratories performed financially?

Ans. Revenue rose from Rs 9,074 crore in FY22 to Rs 11,067 crore in FY26, a compound annual growth rate of 5.1%. Net profit grew from Rs 1,823 crore in FY23 to Rs 2,568 crore in FY26, which works out to a compound annual growth rate of 12.1%. In the June 2026 quarter, revenue grew 24.3% year on year to Rs 3,144 crore, while net profit rose 65.5% to Rs 902 crore. The company has a return on equity of 15.3%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 241,311 crore. The stock trades at a P/E of 82.5, above the industry P/E of 36.0. Looking ahead, the company is a key supplier of ingredients for several widely used generics and has long-standing contract manufacturing relationships with global innovators. Capacity additions at its sites and a growing custom synthesis pipeline support future volumes.

How has Ashok Leyland performed financially?

Ans. Revenue rose from Rs 26,324 crore in FY22 to Rs 56,947 crore in FY26, a compound annual growth rate of 21.3%. Net profit grew from Rs 1,359 crore in FY23 to Rs 3,721 crore in FY26, which works out to a compound annual growth rate of 39.9%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 13,258 crore, while net profit rose 1.5% to Rs 668 crore. The company has a return on equity of 24.4%, a debt to equity ratio of 4.49 and a market capitalisation of Rs 85,729 crore. The stock trades at a P/E of 23.0, below the industry P/E of 23.4. Looking ahead, the company is growing in light commercial vehicles and electric buses and is widening its presence in export markets. Rising freight activity and fleet replacement support steady demand for its trucks and buses.

What risks should investors check before buying specialty chemical, drug input and truck stocks?

Ans. Investors should check a few risks before buying specialty chemical, drug input and truck stocks. Raw material and energy costs. Input prices can move margins in chemicals. Regulatory approvals. Plant inspections and approvals can affect supplies. Production cycles. Vehicle output can vary with demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of specialty chemical, drug input and truck stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.